Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy

Martin-García, Ana; Díaz-Peláez, Elena; Martín-García, Agustín; Sánchez‐González, Javier; Ibáñez, Borja; Sánchez, Pedro L.

doi:10.1016/j.rec.2019.07.006

Cited by 12 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positive effects of S/V on cardiac structure and function in chemotherapy-damaged hearts were also reported recently. A group of patients underwent CMR at baseline, and after 3 months from the beginning of S/V therapy, the findings were consistent with the reverse remodeling of LV volumes, improvement of LVEF, and reduction of NTpro-BNP levels (14).…”

Section: Discussionsupporting

confidence: 66%

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology

Canale

Coviello

Solarino

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Effective anticancer treatments have dramatically improved the outcome of patients with cancer, but cardiac toxicity reduces their clinical efficacy in a non-negligible percentage of patients. Sacubitril/valsartan is a new paradigm in the treatment of chronic heart failure, with a reduced ejection fraction due to the enhancement of natriuretic peptides' properties when coupled with a blocking effect on the angiotensin II type 1 (AT1) receptors. As with other clinical conditions of heart failure with potentially reversible declines in cardiac function, a wearable cardioverter defibrillator (WCD) is a valid tool for protection against sudden death until recovery occurs. We report a case series of four patients with chemotherapy-related acute cardiac failure with severely reduced cardiac function. They were successfully treated with sacubitril/valsartan while being protected from malignant arrhythmias using a wearable cardioverter defibrillator until the recovery of cardiac function. Sacubitril/valsartan was confirmed to be effective in anthracycline-related cardiac toxicity and the wearable cardioverter defibrillator should be considered as a support tool even in the oncology patient.

show abstract

Section: Discussionsupporting

confidence: 66%

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology

Canale

Coviello

Solarino

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Even if the magnitude of ARNI-related reverse remodelling described in previous studies is inferior to that observed in our case, [15][16][17] , other studies showed more considerable changes of left ventricular volumes and ejection fraction. 12,18,19 Moreover, in the present case the observed changes of left ventricular volumes and ejection fraction improvement were rapid, similarly to other reports describing significant reverse remodelling only after switching from standard therapy to sacubitril/valsartan in patients with cardiotoxicity. 20 In conclusion, in this case report of relapsing HCL and HFrEF, early ARNI treatment was feasible, safe and accompanied by significant LVEF improvement.…”

Section: Discussionsupporting

confidence: 89%

“…Sheppard et al 11 presented for the first time data from 2 patients with anthracycline-induced cardiomyopathy successfully managed with ARNI after suboptimal responses to traditional evidencebased heart failure therapies. In another recent case series, Martin-Garcia et al 12 reported the effects of sacubitril/ valsartan on left ventricular ejection fraction (LVEF) and reverse remodelling parameters in 10 consecutive patients with cancer therapy-induced cardiomyopathy and HFrEF evaluated with cardiac magnetic resonance before and 3 months following the initiation of ARNI therapy. In this population, the median time from cancer therapy to HFrEF was 31 months and the drugs employed were mostly anthracyclines.…”

Section: Discussionmentioning

confidence: 99%

Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report

Lupi¹,

Ariotti²,

Pace³

et al. 2021

Clin Med Insights Cardiol

View full text Add to dashboard Cite

Experience with angiotensin-receptor neprilysin inhibitors (ARNI) in oncologic patients with heart failure (HF) is limited. We report a case of ARNI started as first-choice therapy in a patient with relapsing hairy cell leukaemia (HCL) and HF with depressed left ventricular ejection fraction (LVEF). A middle-aged male, previously treated with rituximab for HCL, was scheduled for cardiologic screening before starting a new antineoplastic therapy for cancer relapse. The patient had symptomatic HF with reduced LVEF and high NT-proBNP levels. In this patient, early ARNI treatment was well tolerated and produced a rapid and durable improvement of symptoms, LVEF and NT-proBNP levels. Consequently, the oncologic team could start an experimental treatment with obinutuzumab, with complete HCL remission. In conclusion, in this patient with HCL and HF, ARNI therapy was safe and effective, contributing to undelayed cancer treatment.

show abstract

“…On average, LVEF increased from 33 to 42%. The same authors reported on a group of 10 patients (80% treated with anthracyclines and 10% with trastuzumab), in whom cardiac magnetic resonance (CMR) was performed at baseline and at 3 months follow-up [13]. Results were consistent with S/V reducing LV volumes, improving LVEF (from 35 to 47%) and NTproBNP levels.…”

mentioning

confidence: 78%

In ®Entresto we trust

et al. 2020

View full text Add to dashboard Cite

Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori excluded from the registration study. The value of S/V in this important subgroup of patients needs to be firmly established. In this issue of Cardio-Oncology, Gregorietti et al. report on the effects of S/V in a small group of cancer patients, primarily women with breast cancer treated with anthracyclines. The data are limited but seem to confirm the encouraging results of prior studies, paving the way to foster the use of S/V in cardio-oncology patients and hopefully, to design ad hoc prospective studies in this highly vulnerable population.

show abstract

Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy

Cited by 12 publications

References 2 publications

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology

Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report

In ®Entresto we trust

Contact Info

Product

Resources

About